Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | MMP2 | P08253 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6241872 | 1.00 | TACR1 (0.64) | TACR1MAPTMEN1KMT2ALMNA | |
| SCHEMBL6241313 | 1.00 | TACR1 (0.64) | TACR1MAPTMEN1KMT2ALMNA | |
| SCHEMBL6241302 | 1.00 | TACR1 (0.64) | TACR1MAPTMEN1KMT2ALMNA | |
| SCHEMBL6239886 | 0.94 | TACR1 (0.58) | TACR1MAPTMEN1KMT2ALMNA | |
| SCHEMBL6239892 | 0.94 | TACR1 (0.58) | TACR1MAPTMEN1KMT2ALMNA | |
| SCHEMBL3193567 | 0.91 | TACR1 (0.69) | TACR1MAPTMEN1KMT2ALMNA | |
| SCHEMBL3193569 | 0.91 | TACR1 (0.69) | TACR1MAPTMEN1KMT2ALMNA | |
| SCHEMBL6245999 | 0.90 | MEN1 (0.68) | TACR1MAPTMEN1KMT2ALMNA | |
| SCHEMBL6240498 | 0.90 | MEN1 (0.68) | TACR1MAPTMEN1KMT2ALMNA | |
| SCHEMBL6245757 | 0.90 | MEN1 (0.68) | TACR1MAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1113795-B1 | TRYPTOPHANYL ESTERS AND THEIR N-ACYL DERIVATIVES FOR THE PREVENTION AND TREATMENT OF DISEASES CAUSED OR EXACERBATED BY OXIDATION PROCESSES | MAX PLANCK GESELLSCHAFT (DE) | 2005-07-13 | — | — | EP | claimed |
| US-20040176436-A1 | Tryptophanyl-esters and their N-acyl derivatives for preventing and treating diseases caused or aggravated by oxidation processes | BEHL CHRISTIAN (DE) | 2004-09-09 | — | — | US | claimed |
| US-20010014695-A1 | Tryptophanyl-esters and their n-acyl derivatives for preventing and treating diseases caused or aggravated by oxidation processes | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2001-08-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176436-A1 | Tryptophanyl-esters and their N-acyl derivatives for preventing and treating diseases caused or aggravated by oxidation processes | AADAT, KYNU, AADAC | TACR1 4551/4885MAPT 521/4885MEN1 3270/4885 |
| US-20010014695-A1 | Tryptophanyl-esters and their n-acyl derivatives for preventing and treating diseases caused or aggravated by oxidation processes | AADAT, KYNU, AANAT | TACR1 4354/4885MAPT 409/4885MEN1 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.